Novo Nordisk (NVO.US) exceeded expectations in Q2 performance and raised its full-year guidance, but concerns remain! Sales of the Wegovy oral medication are sluggish, and the path to returning to growth is still overshadowed.

According to the Zhito Finance APP, although Novo Nordisk (NVO.US) reported better-than-expected results for the second quarter of 2026 and raised its full-year guidance, it has not addressed Wall Street's most pressing concern whether this Danish pharmaceutical giant can find a clear path back to sustainable growth amid intensifying competition in the weight loss drug market.